Clinical Trial Update: A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study of JNJ-64407564 in Japanese participants with relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JNJ-64407564

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED